Get the Stockscreener App
27.54
1.25%
0.34
After Hours:
27.01
-0.53
-1.92%
Royalty Pharma Plc stock is traded at $27.54, with a volume of 1.81M.
It is up +1.25% in the last 24 hours and down -0.76% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$27.20
Open:
$27.12
24h Volume:
1.81M
Relative Volume:
0.87
Market Cap:
$12.34B
Revenue:
$2.24B
Net Income/Loss:
$673.24M
P/E Ratio:
244.80
EPS:
0.1125
Net Cash Flow:
$2.67B
1W Performance:
+1.44%
1M Performance:
-0.76%
6M Performance:
-3.06%
1Y Performance:
-1.47%
1-Day Range:
$26.95
$27.57
1-Week Range:
$26.94
$27.59
52-Week Range:
$25.20
$31.66
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com - Defense World
Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com
Royalty Pharma (NASDAQ:RPRX) Raised to "Buy" at StockNews.com - MarketBeat
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - The Manila Times
Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com UK
With 72% ownership, Royalty Pharma plc (NASDAQ:RPRX) boasts of strong institutional backing - Simply Wall St
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by abrdn plc - MarketBeat
Trend Tracker for (RPRX) - Stock Traders Daily
Cannon Global Investment Management LLC Purchases Shares of 34,500 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Blue Trust Inc. - Defense World
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus Price Target from Brokerages - Defense World
Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Hold at StockNews.com - Defense World
Royalty Pharma (RPRX) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq
Royalty Pharma (RPRX) to Release Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Reduces Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Signaturefd LLC Lowers Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
China Universal Asset Management Co. Ltd. Acquires 33,206 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Cut to Hold at StockNews.com - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Price Target Lowered to $40.00 at Citigroup - MarketBeat
Raymond James & Associates Purchases 71,402 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Keene & Associates Inc. Buys Shares of 19,050 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Why Southern, Xcel Energy And Royalty Pharma Are Winners For Passive Income - Yahoo Finance
Royalty Pharma plc (NASDAQ: RPRX) Drops -1.14% In Early Trade; What Lies Ahead? - Stocks Register
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income - The Motley Fool
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Marathon Asset Management Ltd - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Truist Financial Corp - Defense World
Paragon Capital Management Inc. Sells 49,241 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 - The Manila Times
Sanctuary Advisors LLC Invests $649,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21 - Simply Wall St
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21 - Yahoo Finance
(RPRX) Technical Data - Stock Traders Daily
Royalty Pharma plc (NASDAQ:RPRX) Plans $0.21 Quarterly Dividend - MarketBeat
Royalty Pharma announces Q4 dividend of $0.21 per share - Investing.com India
How does Royalty Pharma plc (RPRX) change from a tortoise to a hare? - SETE News
Royalty Pharma announces Q4 dividend of $0.21 per share By Investing.com - Investing.com South Africa
Royalty Pharma Declares Fourth Quarter 2024 Dividend - ForexTV.com
Royalty Pharma plc (RPRX) Declares $0.21 Quarterly Dividend; 3.1% Yield - StreetInsider.com
RPRX’s Market Whiplash: -1.82% YTD Decline, -1.71% Plunge in 30 Days - The InvestChronicle
3 Biotech Stocks With Huge Upside Based on Analyst Price Targets - Inkl
Understanding the Risks of Investing in Royalty Pharma plc (RPRX) - Knox Daily
Royalty Pharma plc (RPRX): Among The Stocks With Biggest Upside Potential According to Hedge Funds - Insider Monkey
Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX) - Simply Wall St
SG Americas Securities LLC Has $1.76 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma shares retain Buy rating on sustainable growth By Investing.com - Investing.com UK
Mackenzie Financial Corp Sells 18,742 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
10 Stocks with Biggest Upside Potential According to Hedge Funds - Insider Monkey
Sei Investments Co. Buys 31,055 Shares of Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RIGGS RORY B | Director |
Jan 03 '24 |
Sale |
27.79 |
199,098 |
5,532,276 |
55,801 |
| RIGGS RORY B | Director |
Jan 04 '24 |
Sale |
27.55 |
35,702 |
983,504 |
20,099 |
| Avara Management Ltd | 10% Owner |
Dec 29 '23 |
Sale |
28.04 |
65,803 |
1,845,406 |
2,477,520 |
| Avara Management Ltd | 10% Owner |
Dec 28 '23 |
Sale |
28.20 |
209,863 |
5,918,934 |
2,543,323 |
| Avara Management Ltd | 10% Owner |
Dec 27 '23 |
Sale |
28.01 |
41,729 |
1,168,754 |
2,753,186 |
| Avara Management Ltd | 10% Owner |
Dec 15 '23 |
Sale |
28.01 |
10,229 |
286,499 |
2,794,915 |
| Avara Management Ltd | 10% Owner |
Dec 14 '23 |
Sale |
28.91 |
364,441 |
10,534,276 |
2,805,144 |
| Avara Management Ltd | 10% Owner |
Dec 13 '23 |
Sale |
28.95 |
307,935 |
8,916,012 |
3,169,585 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):